338960-25-1

Usage

Uses

Used in Pharmaceutical Industry:
5-(Benzyloxy)-2,4-dichloroaniline is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 5-(Benzyloxy)-2,4-dichloroaniline serves as a key intermediate in the production of agrochemicals, aiding in the creation of substances that protect crops and enhance agricultural productivity.
Used in Dye and Pigment Manufacturing:
5-(Benzyloxy)-2,4-dichloroaniline is utilized as a starting material in the manufacturing of dyes and pigments, providing colorants for various industrial applications, including textiles, plastics, and printing inks.
Used in Polymer Production:
5-(BENZYLOXY)-2,4-DICHLOROANILINE is also used in the production of polymers, where it can influence the properties of the final polymer product, such as color, stability, and other performance characteristics.

Upstream product

• 114109-50-1 1-benzyloxy-2,4-dichloro-5-nitrobenzene 

Downstream Products

• 847560-51-4 1-benzyloxy-2,4-dichloro-5-iodobenzene 
• 847559-67-5 2-amino-4-(5-benzyloxy-2,4-dichlorophenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid ethyl ester 
• 847559-68-6 2-amino-4-(2,4-dichloro-5-hydroxyphenyl)thieno[2,3-d]pyrimidine-6-carboxylic acid ethylamide 
• 431942-67-5 2,4-dichloro-5-methoxyphenylboronic acid 
• 950662-12-1 4-(2,4-dichloro-5-methoxyphenyl)-2-methylsulfanyl-7-(2-trimethylsilanyl-ethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 
• 189138-40-7 2,4-dichloro-5-iodo-1-methoxybenzene 
• 335014-73-8 2,4-dichloro-5-iodophenol 
• 950662-17-6 1-[2-(2,4-dichloro-5-iodophenoxy)ethyl]pyrrolidine 

Relevant academic research and scientific papers

Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization

Inhibitors of the Hsp90 molecular chaperone are showing promise as anti-cancer agents. Here we describe a series of 4-aryl-5-cyanopyrrolo[2,3-d] pyrimidine ATP competitive Hsp90 inhibitors that were identified following structure-driven optimization of purine hits revealed by NMR based screening of a proprietary fragment library. Ligand-Hsp90 X-ray structures combined with molecular modeling led to the rational displacement of a conserved water molecule leading to enhanced affinity for Hsp90 as measured by fluorescence polarization, isothermal titration calorimetry and surface plasmon resonance assays. This displacement was achieved with a nitrile group, presenting an example of efficient gain in binding affinity with minimal increase in molecular weight. Some compounds in this chemical series inhibit the proliferation of human cancer cell lines in vitro and cause depletion of oncogenic Hsp90 client proteins and concomitant elevation of the co-chaperone Hsp70. In addition, one compound was demonstrated to be orally bioavailable in the mouse. This work demonstrates the power of structure-based design for the rapid evolution of potent Hsp90 inhibitors and the importance of considering conserved water molecules in drug design.

Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone

Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe novel 2-aminothieno[2,3-d]pyrimidine ATP competitive Hsp90 inhibitors, which were designed

PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER

Compounds of formula (I) are inhibitors of HSP90, and of utility in the treatment of, for example, cancers: wherein ring A is an aryl or heteroaryl ring or ring system; R1 is hydrogen, fluoro, chloro, bromo, or a radical of formula (1A): -X-AIk

PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS

Compounds of formula (I) have HSP90 inhibitory activity and are therefore useful in the treatment of, inter alia, cancer: Formula (I) wherein Ri is hydrogen, fluoro, chloro, bromo, or a radical of formula -X-Alk1-(Z)m-(Alk2)n-Q wherein X is -O-, -S- -S(O)-, -SO2-, or -NH-, Z is -O-, -S-, -(C=O)-, -(C=S)-, -S(O)-, -SO2-, -NRA-, or, in either orientation -C(=O)O-, -C(=O)NRA- , -C(=S)NRA-, -SO2NRA-, -NRAC(=O)-, or -NRASO2- wherein RA is hydrogen or C1-C6 alkyl AIk1 and AIk2 are optionally substituted divalent C1-C3 alkylene or C2-C3 alkenylene radicals, m, n and p are independently 0 or 1 , and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is a radical of formula -(Ar1)p-(Alk1)q-(Z)r-(Alk2)s-Q wherein Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1, Alk2, Z, and Q are as defined above, and p, q, r and s are independently 0 or 1 ; and R3 is cyano (-CN), fluoro, chloro, bromo, methyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, ethyl in which in which one or more hydrogen atoms are optionally replaced by fluorine atoms, cyclopropyl, -OH, -CH2OH, -C(O)NH2, -C(O)CH3, Or -NH2.

PYRIMIDOTHIOPHENE COMPOUNDS

Compounds of formula (I) are inhibitors of HSP90, and useful in the treatment of, for example, cancers: Formula (I) wherein R2 is a group of formula (IA): -(Ar1)m (Alk1)P (Z)r (Alk2/s

PYRIMIDOTHIOPHENE COMPOUNDS FOR USE AS HSP90 INHIBITORS

Certain specific compounds of formula (I) are inhibitors of HSP90 activity in vitro or in vivo, and of use in the treatment ofinter alia, cancer: formula (I) wherein R2 is a group of formula -(Ar1)m-(Alk1)P

PYRIMIDOTHIOPHENE COMPOUNDS

Compounds of formula (1) are inhibitors of HSP90 activity in vitroor in vivo, and of use in the treatment of inter alia, cancer: wherein R2 is a group of formula -(Ar1)m-(Alk1)P-(Z)r-(Alk2)